Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is now up 305% compared to a 12-month low of $0.2. We have seen the price to move -3.66% lower and get settled at $0.81 on 7/11/2019. At recent session, it appeared stuck in a range of $0.7199 to $0.85. This company shares are 538.27% off its target price of $5.17 and the current market capitalization stands at $54.26M. The recent change has given its price a -11.66% deficit over SMA 50 and -68.85% deficit over its 52-week high. The stock witnessed 32.9% gains, -49.69% declines and 65.34% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SNSS’s volatility during a week at 15.4% and during a month it has been found around 17.97%.
What Does Sunesis Pharmaceuticals, Inc. (SNSS) Do?
The company describes itself in regulatory filings as, “Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.” [Text can be found here: https://www.marketwatch.com/investing/stock/SNSS/profile under company description.]Sunesis Pharmaceuticals, Inc. (SNSS) Top Holders
Institutional investors currently hold around $26 million or 57.9% in SNSS stock. Look at its top three institutional owners: Aisling Capital Management Lp owns $6.39 million in Sunesis Pharmaceuticals, Inc., which represents roughly 11.78% of the company’s market cap and approximately 24.58% of the institutional ownership. Similar statistics are true for the second largest owner, Eventide Asset Management, Llc, which owns 5,965,455 shares of the stock are valued at $5.02 million. The third largest holder is Samsara Biocapital, Llc, which currently holds $3.15 million worth of this stock and that ownership represents nearly 5.81% of its market capitalization.
At the end of March reporting period, 24 institutional holders increased their position in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by some 16,835,913 shares, 10 decreased positions by 1,003,614 and 18 held positions by 13,419,798. That puts total institutional holdings at 31,259,325 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 6,203,318 shares while 5 institutional investors sold out their entire positions totaling 897,876 shares.Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Insider Trades
Multiple company employees have indulged in significant insider trading. Sunesis Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO,Sr.V.P. Finance, Corp.Dev. Quinn William P. has acquired 40,000 shares of Sunesis Pharmaceuticals, Inc. (SNSS) in the trading session dated Dec. 10, 2018. These shares are worth $18,800 and were traded at $0.47 each. The SEC filing shows that MPM Oncology Impact Management performed a purchase of 81,500 shares. The 10% Owner added these shares by way of transaction on Nov. 06, 2017. The company’s shares were assimilated at $2.77 per share worth to an investment of some $225,755 to the account of MPM Oncology Impact Management.
Director, Misfeldt Dayton, purchased 400,000 common shares of Sunesis Pharmaceuticals, Inc. (SNSS) in the open market. In a transaction dated Oct. 27, 2017, the shares were bought at an average price of $2, giving away a sum of $800,000. After this purchase, 252 common shares of SNSS are directly owned by the insider, with total stake valued at $204.
In the transaction dated Dec. 09, 2016, a great number of shares acquired came courtesy the Director; Parker Geoffrey M. added a total of 3,740 shares at an average price of $3.87, amounting to approximately $14,474. The insider now directly owns 14,074 shares worth $11,400.Sunesis Pharmaceuticals, Inc. (SNSS) Analyst Guide
Several analysts have released their opinion on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), with 2 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].